<\/strong><\/span><\/h4>\n<\/strong><\/span><\/h4>\nC.\u0218.I. Dr. Neagu Monica<\/strong><\/span>
Institutul Na\u0163ional \u201cVictor Babe\u015f\u201d, Bucure\u015fti<\/strong><\/span>
Spitalul Clinic \u201dColentina\u201d, Bucure\u015fti<\/strong><\/span><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″]<\/p>\n
Imunoterapia \u00een melanomul cutanat \u2013 ce urmeaz\u0103? <\/span>
Autori: Monica Neagu, Carolina Constantin, Sabina Zurac<\/span><\/p>\nEra noilor terapii \u00een melanomul cutanat a fost deschis\u0103 de aprobarea primelor imunoterapii. Odat\u0103 cu intrarea \u00een clinica a acestor terapii, o serie de \u00eentreb\u0103ri \u00eencep s\u0103 se ridice at\u00e2t din punct de vedere al cercet\u0103rii fundamentale c\u00e2t \u015fi al managementului pacientului cu melanom cutanat supus acestor terapii.
\u00cen anul care a trecut o serie de Conferin\u0163e Interna\u0163ionale de Dermatologie, Dermato-oncologie \u015fi Imunoterapie au subliniat c\u0103ile de cercetare care se deschid \u00een urma implement\u0103rii \u00een clinic\u0103 a imunoterapiilor \u00een melanomul cutanat.
Astfel, f\u0103r\u0103 a fi exhaustivi \u00een prezentarea noastr\u0103 vom prezenta c\u00e2teva dintre aceste c\u0103i de urmat \u00een viitorii ani \u00een aceast\u0103 patologie. Odat\u0103 cu intrarea \u00een practica medical\u0103 a imunoterapiilor date privind efectele secundare pe scurt\u0103 \u015fi lung\u0103 durat\u0103 \u00eencep s\u0103 se acumuleze. Aceste efecte secundare acoper\u0103 o diversitate extrem de mare \u015fi managementul acestora \u015fi al pacientului supus imunoterapiei trebuie s\u0103 \u0163in\u0103 seama de gravitatea, durata \u015fi tipul acestor efecte secundare asociate cu eventualele co-morbidit\u0103\u0163i ale individului tratat. \u00cen plus imunoterapiile \u015fi eficien\u0163a acestora au anumite durate \u00een timp, astfel \u00eenc\u00e2t dob\u00e2ndirea rezisten\u0163ei la aceste terapii trebuie \u00eenso\u0163it\u0103 de schimbarea planului de tratament.
Pentru \u0163intirea concomitent\u0103 a diverselor c\u0103i implicate \u00een dob\u00e2ndirea rezisten\u0163ei, aplicarea combina\u0163iilor de imunoterapie reprezint\u0103 o solu\u0163ie. Se pot combina imunoterapii \u201cclasice\u201d sau, aflate \u00een etapele de studii clinice, se pot combina noi imunoterapii. \u00cen cadrul acestor demersuri terapeutice dozele \u015fi dinamica aplic\u0103rii lor este \u00eenso\u0163it\u0103 de stabilirea grupelor de pacien\u0163i la care aceste combina\u0163ii de imunoterapii sunt eficiente.
\u00cen stadiile de testare clinic\u0103 exist\u0103 \u015fi o serie de noi imunoterapii. Astfel o nou\u0103 cale de abordare terapeutic\u0103 este reprezentat\u0103 de ac\u0163iunea virusurilor oncolitice modificate genetic av\u00e2nd drept scop eficientizarea terapiei, iar \u00een acest sens terapia T-VEC va fi prezentat\u0103.
Nu \u00een ultimul r\u00e2nd, tendin\u0163a interna\u0163ional\u0103 \u00een domeniu este de a identifica noi biomarkeri sau noi combina\u0163ii de biomarkeri care pot stratifica pacien\u0163ii, pot previziona eficien\u0163a imuno-terapiei instituite, pot indica momentul apari\u0163iei rezisten\u0163ei \u015fi pot orienta re-instituirea unui alt tip de imuno-terapie.
Acknowledgement. PN-III-P1-1.2-PCCDI-2017-0341\/2018, EPITRAN COST ACTION 16120\/2018<\/p>\n
Up-dates in cutaneous melanoma immunotherapy<\/span>
Authors: Monica Neagu, Carolina Constantin, Sabina Zurac<\/span><\/p>\nWith the advent of the new era of immune-therapy, new rapidly emerging aspects are highlighted from both fundamental research and clinical applications.
Recently highlighted in several Dermato-oncology International Congresses have identified the actual trends in melanoma therapy and, far from being exhaustive, we will pinpoint a few. Therefore, one of the most important points in melanoma immuno-therapy is that, due to the approval of several immune-related therapies we are gaining experience from clinical application in terms of adverse effects types, management of them, acquiring resistance, overcoming resistance, using adjuvant therapies and seeking for the best prognosis\/efficacy biomarkers.
Another recent trend in this domain is combining newly approved immune-related therapies, looking for best time frame, drug(s) concentration and stratifying patients for the combination. Besides the \u201cclassical one\u201d, some new combination of immune therapy approaches will be presented, approaches that are in the clinical trials pipeline.
The limitations of current immune therapy approaches can be bypassed by designing new ones. Thus, actually newly approved drugs have triggered the design of new ones like oncolitic viruses. In this frame T-VEC oncolitic therapy will be presented. Last, but not least newly discovered biomarkers or combination of biomarkers that can better predict immune-related therapy efficacy will be presented.
Acknowledgement. PN-III-P1-1.2-PCCDI-2017-0341\/2018, EPITRAN COST ACTION 16120\/2018<\/p>\n
Scurt CV<\/span><\/p>\nCS I, Profesor abilitat, \u015eef Laborator Imunologie, Institutul Na\u0163ional \u201cVictor Babes\u201d, Bucure\u015fti, Coordonator de Doctorat Facultatea de Biologie, Universitatea Bucure\u015fti, CS I \u00een colectivul de cercetare al Departamentului de Anatomie Patologic\u0103, Spitalul Clinic \u201dColentina\u201d, Bucure\u015fti.
1996 \u2013 Doctoratul \u00een Imunologie \u00een cotutel\u0103 cu Departamentul R&D Novartis, Ltd, Elvetia; din anul 2000 \u015eef de Laborator \u015fi din anul 2014 Profesor abilitat de Imunologie. \u00cen ultimii 5 ani a condus \u015fi participat \u00een peste 10 proiecte na\u0163ionale \u015fi 5 proiecte cu Fonduri structurale EU \u00een domeniul bio-medical, imunologie, proteomic\u0103, toxicologie. A fost membru \u00een echipe de cercetare interna\u0163ionale \u00een proiecte ERA-NET, FP7, Horizon2020. A condus proiecte interna\u0163ionale de cooperare bilateral\u0103 Rom\u00e2nia-China 511\/2011 cu Beijing Institute of Genomics, cooperare bilateral\u0103 Rom\u00e2nia-Grecia 7285\/02 cu University of Athens.
A fost director de proiect NATO SfP 982838\/2007 cu University of Tubingen. A fost membru al echipei de management pentru re\u0163eaua interna\u0163ional\u0103 COST Action D39, actualmente este membru al echipei de management pentru re\u0163elele interna\u0163ionale COST Action 16120\/2018 EPITRAN \u015fi COST Action 18125\/2019 AeroGels. Este co-inventator la 7 brevete de inven\u0163ie \u00een domeniul dermato-patologiei \u015fi dermato-oncologiei, brevete cu numeroase premii nterna\u0163ionale.
\u00cen perioada 2010-2013 a fost membru al Comisiei pentru Terapii Avansate \u2013 EMEA. Editor pentru c\u0103r\u0163i \u00een Edituri interna\u0163ionale, Editor pentru numere speciale \u00een reviste interna\u0163ionale Disease Markers, Journal of Immunology Research. Editor Asociat pentru Journal of Immunoassay and Immunochemistry. Evaluator pentru proiecte na\u0163ionale \u015fi interna\u0163ionale, evaluator la peste 50 de reviste interna\u0163ionale. Membru \u00een Editorial board pentru numeroase reviste interna\u0163ionale.
A publicat peste 100 de articole \u015ftiin\u0163ifice indexate ISI cu peste 1500 de cit\u0103ri, acumul\u00e2nd un Hirsch index de 17 (Clarivate), 21 (Google Academics).<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical”][et_pb_row _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false” column_structure=”3_5,2_5″][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2019<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”3.19.4″ title_font=”||||||||”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2019<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”3.27.4″ text_font=”||||||||”]![\"\"](\"https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/eventer_logo_150px.png\")
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
\nTel.: 0332.40.88.00-05<\/span>
\nE-mail: inscrieri@pdi.ro\/2019<\/a>
\n<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"C.\u0218.I. Dr. Neagu Monica Institutul Na\u0163ional \u201cVictor Babe\u015f\u201d, Bucure\u015fti Spitalul Clinic \u201dColentina\u201d, Bucure\u015ftiImunoterapia \u00een melanomul cutanat \u2013 ce urmeaz\u0103? Autori: Monica Neagu, Carolina Constantin, Sabina Zurac Era noilor terapii \u00een melanomul cutanat a fost deschis\u0103 de aprobarea primelor imunoterapii. Odat\u0103 cu intrarea \u00een clinica a acestor terapii, o serie de \u00eentreb\u0103ri \u00eencep s\u0103 se ridice […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"class_list":["post-4753","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/4753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/comments?post=4753"}],"version-history":[{"count":5,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/4753\/revisions"}],"predecessor-version":[{"id":6737,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/4753\/revisions\/6737"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/media?parent=4753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
C.\u0218.I. Dr. Neagu Monica<\/strong><\/span>
Institutul Na\u0163ional \u201cVictor Babe\u015f\u201d, Bucure\u015fti<\/strong><\/span>
Spitalul Clinic \u201dColentina\u201d, Bucure\u015fti<\/strong><\/span><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″]<\/p>\n
Imunoterapia \u00een melanomul cutanat \u2013 ce urmeaz\u0103? <\/span>
Autori: Monica Neagu, Carolina Constantin, Sabina Zurac<\/span><\/p>\nEra noilor terapii \u00een melanomul cutanat a fost deschis\u0103 de aprobarea primelor imunoterapii. Odat\u0103 cu intrarea \u00een clinica a acestor terapii, o serie de \u00eentreb\u0103ri \u00eencep s\u0103 se ridice at\u00e2t din punct de vedere al cercet\u0103rii fundamentale c\u00e2t \u015fi al managementului pacientului cu melanom cutanat supus acestor terapii.
\u00cen anul care a trecut o serie de Conferin\u0163e Interna\u0163ionale de Dermatologie, Dermato-oncologie \u015fi Imunoterapie au subliniat c\u0103ile de cercetare care se deschid \u00een urma implement\u0103rii \u00een clinic\u0103 a imunoterapiilor \u00een melanomul cutanat.
Astfel, f\u0103r\u0103 a fi exhaustivi \u00een prezentarea noastr\u0103 vom prezenta c\u00e2teva dintre aceste c\u0103i de urmat \u00een viitorii ani \u00een aceast\u0103 patologie. Odat\u0103 cu intrarea \u00een practica medical\u0103 a imunoterapiilor date privind efectele secundare pe scurt\u0103 \u015fi lung\u0103 durat\u0103 \u00eencep s\u0103 se acumuleze. Aceste efecte secundare acoper\u0103 o diversitate extrem de mare \u015fi managementul acestora \u015fi al pacientului supus imunoterapiei trebuie s\u0103 \u0163in\u0103 seama de gravitatea, durata \u015fi tipul acestor efecte secundare asociate cu eventualele co-morbidit\u0103\u0163i ale individului tratat. \u00cen plus imunoterapiile \u015fi eficien\u0163a acestora au anumite durate \u00een timp, astfel \u00eenc\u00e2t dob\u00e2ndirea rezisten\u0163ei la aceste terapii trebuie \u00eenso\u0163it\u0103 de schimbarea planului de tratament.
Pentru \u0163intirea concomitent\u0103 a diverselor c\u0103i implicate \u00een dob\u00e2ndirea rezisten\u0163ei, aplicarea combina\u0163iilor de imunoterapie reprezint\u0103 o solu\u0163ie. Se pot combina imunoterapii \u201cclasice\u201d sau, aflate \u00een etapele de studii clinice, se pot combina noi imunoterapii. \u00cen cadrul acestor demersuri terapeutice dozele \u015fi dinamica aplic\u0103rii lor este \u00eenso\u0163it\u0103 de stabilirea grupelor de pacien\u0163i la care aceste combina\u0163ii de imunoterapii sunt eficiente.
\u00cen stadiile de testare clinic\u0103 exist\u0103 \u015fi o serie de noi imunoterapii. Astfel o nou\u0103 cale de abordare terapeutic\u0103 este reprezentat\u0103 de ac\u0163iunea virusurilor oncolitice modificate genetic av\u00e2nd drept scop eficientizarea terapiei, iar \u00een acest sens terapia T-VEC va fi prezentat\u0103.
Nu \u00een ultimul r\u00e2nd, tendin\u0163a interna\u0163ional\u0103 \u00een domeniu este de a identifica noi biomarkeri sau noi combina\u0163ii de biomarkeri care pot stratifica pacien\u0163ii, pot previziona eficien\u0163a imuno-terapiei instituite, pot indica momentul apari\u0163iei rezisten\u0163ei \u015fi pot orienta re-instituirea unui alt tip de imuno-terapie.
Acknowledgement. PN-III-P1-1.2-PCCDI-2017-0341\/2018, EPITRAN COST ACTION 16120\/2018<\/p>\n
Up-dates in cutaneous melanoma immunotherapy<\/span>
Authors: Monica Neagu, Carolina Constantin, Sabina Zurac<\/span><\/p>\nWith the advent of the new era of immune-therapy, new rapidly emerging aspects are highlighted from both fundamental research and clinical applications.
Recently highlighted in several Dermato-oncology International Congresses have identified the actual trends in melanoma therapy and, far from being exhaustive, we will pinpoint a few. Therefore, one of the most important points in melanoma immuno-therapy is that, due to the approval of several immune-related therapies we are gaining experience from clinical application in terms of adverse effects types, management of them, acquiring resistance, overcoming resistance, using adjuvant therapies and seeking for the best prognosis\/efficacy biomarkers.
Another recent trend in this domain is combining newly approved immune-related therapies, looking for best time frame, drug(s) concentration and stratifying patients for the combination. Besides the \u201cclassical one\u201d, some new combination of immune therapy approaches will be presented, approaches that are in the clinical trials pipeline.
The limitations of current immune therapy approaches can be bypassed by designing new ones. Thus, actually newly approved drugs have triggered the design of new ones like oncolitic viruses. In this frame T-VEC oncolitic therapy will be presented. Last, but not least newly discovered biomarkers or combination of biomarkers that can better predict immune-related therapy efficacy will be presented.
Acknowledgement. PN-III-P1-1.2-PCCDI-2017-0341\/2018, EPITRAN COST ACTION 16120\/2018<\/p>\n
Scurt CV<\/span><\/p>\nCS I, Profesor abilitat, \u015eef Laborator Imunologie, Institutul Na\u0163ional \u201cVictor Babes\u201d, Bucure\u015fti, Coordonator de Doctorat Facultatea de Biologie, Universitatea Bucure\u015fti, CS I \u00een colectivul de cercetare al Departamentului de Anatomie Patologic\u0103, Spitalul Clinic \u201dColentina\u201d, Bucure\u015fti.
1996 \u2013 Doctoratul \u00een Imunologie \u00een cotutel\u0103 cu Departamentul R&D Novartis, Ltd, Elvetia; din anul 2000 \u015eef de Laborator \u015fi din anul 2014 Profesor abilitat de Imunologie. \u00cen ultimii 5 ani a condus \u015fi participat \u00een peste 10 proiecte na\u0163ionale \u015fi 5 proiecte cu Fonduri structurale EU \u00een domeniul bio-medical, imunologie, proteomic\u0103, toxicologie. A fost membru \u00een echipe de cercetare interna\u0163ionale \u00een proiecte ERA-NET, FP7, Horizon2020. A condus proiecte interna\u0163ionale de cooperare bilateral\u0103 Rom\u00e2nia-China 511\/2011 cu Beijing Institute of Genomics, cooperare bilateral\u0103 Rom\u00e2nia-Grecia 7285\/02 cu University of Athens.
A fost director de proiect NATO SfP 982838\/2007 cu University of Tubingen. A fost membru al echipei de management pentru re\u0163eaua interna\u0163ional\u0103 COST Action D39, actualmente este membru al echipei de management pentru re\u0163elele interna\u0163ionale COST Action 16120\/2018 EPITRAN \u015fi COST Action 18125\/2019 AeroGels. Este co-inventator la 7 brevete de inven\u0163ie \u00een domeniul dermato-patologiei \u015fi dermato-oncologiei, brevete cu numeroase premii nterna\u0163ionale.
\u00cen perioada 2010-2013 a fost membru al Comisiei pentru Terapii Avansate \u2013 EMEA. Editor pentru c\u0103r\u0163i \u00een Edituri interna\u0163ionale, Editor pentru numere speciale \u00een reviste interna\u0163ionale Disease Markers, Journal of Immunology Research. Editor Asociat pentru Journal of Immunoassay and Immunochemistry. Evaluator pentru proiecte na\u0163ionale \u015fi interna\u0163ionale, evaluator la peste 50 de reviste interna\u0163ionale. Membru \u00een Editorial board pentru numeroase reviste interna\u0163ionale.
A publicat peste 100 de articole \u015ftiin\u0163ifice indexate ISI cu peste 1500 de cit\u0103ri, acumul\u00e2nd un Hirsch index de 17 (Clarivate), 21 (Google Academics).<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical”][et_pb_row _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false” column_structure=”3_5,2_5″][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2019<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”3.19.4″ title_font=”||||||||”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2019<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”3.27.4″ text_font=”||||||||”]<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
\nTel.: 0332.40.88.00-05<\/span>
\nE-mail: inscrieri@pdi.ro\/2019<\/a>
\n<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"C.\u0218.I. Dr. Neagu Monica Institutul Na\u0163ional \u201cVictor Babe\u015f\u201d, Bucure\u015fti Spitalul Clinic \u201dColentina\u201d, Bucure\u015ftiImunoterapia \u00een melanomul cutanat \u2013 ce urmeaz\u0103? Autori: Monica Neagu, Carolina Constantin, Sabina Zurac Era noilor terapii \u00een melanomul cutanat a fost deschis\u0103 de aprobarea primelor imunoterapii. Odat\u0103 cu intrarea \u00een clinica a acestor terapii, o serie de \u00eentreb\u0103ri \u00eencep s\u0103 se ridice […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"class_list":["post-4753","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/4753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/comments?post=4753"}],"version-history":[{"count":5,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/4753\/revisions"}],"predecessor-version":[{"id":6737,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/4753\/revisions\/6737"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/media?parent=4753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Autori: Monica Neagu, Carolina Constantin, Sabina Zurac<\/span><\/p>\n
Era noilor terapii \u00een melanomul cutanat a fost deschis\u0103 de aprobarea primelor imunoterapii. Odat\u0103 cu intrarea \u00een clinica a acestor terapii, o serie de \u00eentreb\u0103ri \u00eencep s\u0103 se ridice at\u00e2t din punct de vedere al cercet\u0103rii fundamentale c\u00e2t \u015fi al managementului pacientului cu melanom cutanat supus acestor terapii.
\u00cen anul care a trecut o serie de Conferin\u0163e Interna\u0163ionale de Dermatologie, Dermato-oncologie \u015fi Imunoterapie au subliniat c\u0103ile de cercetare care se deschid \u00een urma implement\u0103rii \u00een clinic\u0103 a imunoterapiilor \u00een melanomul cutanat.
Astfel, f\u0103r\u0103 a fi exhaustivi \u00een prezentarea noastr\u0103 vom prezenta c\u00e2teva dintre aceste c\u0103i de urmat \u00een viitorii ani \u00een aceast\u0103 patologie. Odat\u0103 cu intrarea \u00een practica medical\u0103 a imunoterapiilor date privind efectele secundare pe scurt\u0103 \u015fi lung\u0103 durat\u0103 \u00eencep s\u0103 se acumuleze. Aceste efecte secundare acoper\u0103 o diversitate extrem de mare \u015fi managementul acestora \u015fi al pacientului supus imunoterapiei trebuie s\u0103 \u0163in\u0103 seama de gravitatea, durata \u015fi tipul acestor efecte secundare asociate cu eventualele co-morbidit\u0103\u0163i ale individului tratat. \u00cen plus imunoterapiile \u015fi eficien\u0163a acestora au anumite durate \u00een timp, astfel \u00eenc\u00e2t dob\u00e2ndirea rezisten\u0163ei la aceste terapii trebuie \u00eenso\u0163it\u0103 de schimbarea planului de tratament.
Pentru \u0163intirea concomitent\u0103 a diverselor c\u0103i implicate \u00een dob\u00e2ndirea rezisten\u0163ei, aplicarea combina\u0163iilor de imunoterapie reprezint\u0103 o solu\u0163ie. Se pot combina imunoterapii \u201cclasice\u201d sau, aflate \u00een etapele de studii clinice, se pot combina noi imunoterapii. \u00cen cadrul acestor demersuri terapeutice dozele \u015fi dinamica aplic\u0103rii lor este \u00eenso\u0163it\u0103 de stabilirea grupelor de pacien\u0163i la care aceste combina\u0163ii de imunoterapii sunt eficiente.
\u00cen stadiile de testare clinic\u0103 exist\u0103 \u015fi o serie de noi imunoterapii. Astfel o nou\u0103 cale de abordare terapeutic\u0103 este reprezentat\u0103 de ac\u0163iunea virusurilor oncolitice modificate genetic av\u00e2nd drept scop eficientizarea terapiei, iar \u00een acest sens terapia T-VEC va fi prezentat\u0103.
Nu \u00een ultimul r\u00e2nd, tendin\u0163a interna\u0163ional\u0103 \u00een domeniu este de a identifica noi biomarkeri sau noi combina\u0163ii de biomarkeri care pot stratifica pacien\u0163ii, pot previziona eficien\u0163a imuno-terapiei instituite, pot indica momentul apari\u0163iei rezisten\u0163ei \u015fi pot orienta re-instituirea unui alt tip de imuno-terapie.
Acknowledgement. PN-III-P1-1.2-PCCDI-2017-0341\/2018, EPITRAN COST ACTION 16120\/2018<\/p>\n
Up-dates in cutaneous melanoma immunotherapy<\/span> With the advent of the new era of immune-therapy, new rapidly emerging aspects are highlighted from both fundamental research and clinical applications. Scurt CV<\/span><\/p>\n CS I, Profesor abilitat, \u015eef Laborator Imunologie, Institutul Na\u0163ional \u201cVictor Babes\u201d, Bucure\u015fti, Coordonator de Doctorat Facultatea de Biologie, Universitatea Bucure\u015fti, CS I \u00een colectivul de cercetare al Departamentului de Anatomie Patologic\u0103, Spitalul Clinic \u201dColentina\u201d, Bucure\u015fti. [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2019\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical”][et_pb_row _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false” column_structure=”3_5,2_5″][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n Contacteaz\u0103 operatorul PDI 2019<\/p>\n [\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”3.19.4″ title_font=”||||||||”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n Operatorul PDI 2019<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”3.27.4″ text_font=”||||||||”] <\/span><\/p>\n <\/span><\/p>\n Adresa: Str. A. Panu nr. 13, Iasi<\/span> C.\u0218.I. Dr. Neagu Monica Institutul Na\u0163ional \u201cVictor Babe\u015f\u201d, Bucure\u015fti Spitalul Clinic \u201dColentina\u201d, Bucure\u015ftiImunoterapia \u00een melanomul cutanat \u2013 ce urmeaz\u0103? Autori: Monica Neagu, Carolina Constantin, Sabina Zurac Era noilor terapii \u00een melanomul cutanat a fost deschis\u0103 de aprobarea primelor imunoterapii. Odat\u0103 cu intrarea \u00een clinica a acestor terapii, o serie de \u00eentreb\u0103ri \u00eencep s\u0103 se ridice […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"class_list":["post-4753","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/4753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/comments?post=4753"}],"version-history":[{"count":5,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/4753\/revisions"}],"predecessor-version":[{"id":6737,"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/pages\/4753\/revisions\/6737"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2019\/wp-json\/wp\/v2\/media?parent=4753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Authors: Monica Neagu, Carolina Constantin, Sabina Zurac<\/span><\/p>\n
Recently highlighted in several Dermato-oncology International Congresses have identified the actual trends in melanoma therapy and, far from being exhaustive, we will pinpoint a few. Therefore, one of the most important points in melanoma immuno-therapy is that, due to the approval of several immune-related therapies we are gaining experience from clinical application in terms of adverse effects types, management of them, acquiring resistance, overcoming resistance, using adjuvant therapies and seeking for the best prognosis\/efficacy biomarkers.
Another recent trend in this domain is combining newly approved immune-related therapies, looking for best time frame, drug(s) concentration and stratifying patients for the combination. Besides the \u201cclassical one\u201d, some new combination of immune therapy approaches will be presented, approaches that are in the clinical trials pipeline.
The limitations of current immune therapy approaches can be bypassed by designing new ones. Thus, actually newly approved drugs have triggered the design of new ones like oncolitic viruses. In this frame T-VEC oncolitic therapy will be presented. Last, but not least newly discovered biomarkers or combination of biomarkers that can better predict immune-related therapy efficacy will be presented.
Acknowledgement. PN-III-P1-1.2-PCCDI-2017-0341\/2018, EPITRAN COST ACTION 16120\/2018<\/p>\n
1996 \u2013 Doctoratul \u00een Imunologie \u00een cotutel\u0103 cu Departamentul R&D Novartis, Ltd, Elvetia; din anul 2000 \u015eef de Laborator \u015fi din anul 2014 Profesor abilitat de Imunologie. \u00cen ultimii 5 ani a condus \u015fi participat \u00een peste 10 proiecte na\u0163ionale \u015fi 5 proiecte cu Fonduri structurale EU \u00een domeniul bio-medical, imunologie, proteomic\u0103, toxicologie. A fost membru \u00een echipe de cercetare interna\u0163ionale \u00een proiecte ERA-NET, FP7, Horizon2020. A condus proiecte interna\u0163ionale de cooperare bilateral\u0103 Rom\u00e2nia-China 511\/2011 cu Beijing Institute of Genomics, cooperare bilateral\u0103 Rom\u00e2nia-Grecia 7285\/02 cu University of Athens.
A fost director de proiect NATO SfP 982838\/2007 cu University of Tubingen. A fost membru al echipei de management pentru re\u0163eaua interna\u0163ional\u0103 COST Action D39, actualmente este membru al echipei de management pentru re\u0163elele interna\u0163ionale COST Action 16120\/2018 EPITRAN \u015fi COST Action 18125\/2019 AeroGels. Este co-inventator la 7 brevete de inven\u0163ie \u00een domeniul dermato-patologiei \u015fi dermato-oncologiei, brevete cu numeroase premii nterna\u0163ionale.
\u00cen perioada 2010-2013 a fost membru al Comisiei pentru Terapii Avansate \u2013 EMEA. Editor pentru c\u0103r\u0163i \u00een Edituri interna\u0163ionale, Editor pentru numere speciale \u00een reviste interna\u0163ionale Disease Markers, Journal of Immunology Research. Editor Asociat pentru Journal of Immunoassay and Immunochemistry. Evaluator pentru proiecte na\u0163ionale \u015fi interna\u0163ionale, evaluator la peste 50 de reviste interna\u0163ionale. Membru \u00een Editorial board pentru numeroase reviste interna\u0163ionale.
A publicat peste 100 de articole \u015ftiin\u0163ifice indexate ISI cu peste 1500 de cit\u0103ri, acumul\u00e2nd un Hirsch index de 17 (Clarivate), 21 (Google Academics).<\/p>\n<\/span><\/p>\n
\nTel.: 0332.40.88.00-05<\/span>
\nE-mail: inscrieri@pdi.ro\/2019<\/a>
\n<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"